Drug Trial Radar · NCT03013400
Ebselen as an add-on Treatment in Hypo/Mania
Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Oct 1, 2017
Primary completion
Jul 9, 2019
Study completion Jul 9, 2019
Sponsor
- Lead sponsor
- University of OxfordAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stanley Medical Research Institute; Sound Pharmaceuticals, Incorporated
- First posted
- Jan 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the effect of a 'lithium like' drug called ebselen (SP-1005) versus placebo as an 'add on' treatment to help stabilise hypo/manic symptoms in bipolar disorder. Half of the participants will receive ebselen and the other half placebo. The trial, will last a total of four weeks.
Conditions
- Bipolar Disorder
- Bipolar Disorder, Manic
Interventions
EbselenDrug
Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
Placebo oral capsuleDrug
Placebo is identical in appearance to the ebselen capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Young Mania Rating Scale (YMRS)Time frame: Change between groups, every week, up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neurosciences Building, Dept. Psychiatry, Warneford Hospital
Oxford, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.